Literature DB >> 9194209

Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis.

H Tiwana1, C Wilson, R S Walmsley, A J Wakefield, M S Smith, N L Cox, M J Hudson, A Ebringer.   

Abstract

Specific immunoreactive anti-Klebsiella antibodies are found in patients with ankylosing spondylitis (AS), a significant proportion of whom have occult inflammatory bowel disease. Molecular mimicry between Klebsiella or other bacterial antigens and HLA-B27 has been suggested in the pathogenesis of AS. The specificity of increased immunoreactivity against Klebsiella remains to be assessed against the abundant anaerobic bacterial flora, present either in healthy controls or in patients with ulcerative colitis (UC) and Crohn's disease (CD). Total immunoglobulin (Ig; IgG, IgA, IgM) immunoreactivity was measured by ELISA against Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli and ten anaerobic isolates of the predominant normal bowel flora in 35 patients with active AS, 60 patients with inflammatory bowel disease (30 CD, 30 UC), 60 patients with active rheumatoid arthritis (RA) and 60 healthy controls. Ig immunoreactivity to K. pneumoniae was significantly elevated in AS (P < 0.001), CD (P < 0.001) and UC (P < 0.001) patients compared with RA patients and healthy controls. Furthermore, Ig immunoreactivity to P. mirabilis was significantly elevated only in RA patients, compared with the other inflammatory groups (P < 0.001) and controls (P < 0.001). There was no significant antibody response against E. coli or the ten obligate anaerobes in any of the test groups. The data suggested an increased immune response to Klebsiella in patients with AS, UC, CD and to Proteus in patients with RA. The specificity of these responses in some patients supported a possible role for enteric Klebsiella in the pathogenesis of AS and Proteus in RA. The role of Klebsiella in inflammatory bowel disease requires further study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194209     DOI: 10.1007/pl00006845

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Liaison between rheumatoid arthritis and ulcerative colitis.

Authors:  Yusuf Aydin; Levent Ozçakar; Mehmet Yildiz; Ayşen Akinci
Journal:  Rheumatol Int       Date:  2002-12-18       Impact factor: 2.631

Review 3.  A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.

Authors:  Alan Ebringer; Taha Rashid; Harmale Tiwana; Clyde Wilson
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 2.980

4.  Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis.

Authors:  Uri Gophna; Katrin Sommerfeld; Sharon Gophna; W Ford Doolittle; Sander J O Veldhuyzen van Zanten
Journal:  J Clin Microbiol       Date:  2006-09-20       Impact factor: 5.948

Review 5.  Clinical connection between rheumatoid arthritis and liver damage.

Authors:  Biljana Radovanović-Dinić; Snežana Tešić-Rajković; Valentina Zivkovic; Saša Grgov
Journal:  Rheumatol Int       Date:  2018-04-07       Impact factor: 2.631

6.  Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues.

Authors:  R S Walmsley; A Anthony; R Sim; R E Pounder; A J Wakefield
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

Review 7.  Altered gut microbiota in RA: implications for treatment.

Authors:  Y Kang; Y Cai; X Zhang; X Kong; J Su
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

8.  The potential of selected South African plants with anti-Klebsiella activity for the treatment and prevention of ankylosing spondylitis.

Authors:  I E Cock; S F van Vuuren
Journal:  Inflammopharmacology       Date:  2014-11-21       Impact factor: 4.473

9.  Inhibition of Klebsiella pneumoniae growth by selected Australian plants: natural approaches for the prevention and management of ankylosing spondylitis.

Authors:  V Winnett; J Sirdaarta; A White; F M Clarke; I E Cock
Journal:  Inflammopharmacology       Date:  2017-02-27       Impact factor: 4.473

10.  Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study.

Authors:  N Feltelius; A Ekbom; P Blomqvist
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.